Siddharth Kunte

Siddharth Kunte

Auto-generated profile, based on publicly available information

Siddharth Kunte

Taussig Cancer Institute, Cleveland Clinic, Cleveland, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 July 2020 in Cancer
Verified
Journal Article
Closed access
PDF file
SKSiddharth Kunte
Siddharth Kunte
JAJame Abraham
Jame Abraham
Alberto J MonteroAlberto J Montero
Alberto J Montero

23 March 2021 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
AVAnna M Varghese
Anna M Varghese
ISIsha Singh
Isha Singh
RSRitu Raj Singh
Ritu Raj Singh
SKSiddharth Kunte
Siddharth Kunte
JCJoanne F Chou
Joanne F Chou
Eileen O'ReillyEileen O'Reilly
Eileen O'Reilly
Recent evidence suggests a rising incidence of cancer in younger individuals. Herein, we report the epidemiologic, pathologic, and molecular characteristics of a patient cohort with early-onset pancreas cancer (EOPC). Institutional databases were queried for demographics, treatment history, genomic results, and outcomes. Overall survival from date of diagnosis was estimated using Kaplan-Meier method. Between 2008 and 2018, 450 patients with EOPC were identified at Memorial Sloan Kettering. Median overall survival was 16.3 (95% confidence interval [CI] = 14.6 to 17.7) months in the entire cohort and 11.3 (95% CI = 10.2 to 12.2) months for patients with stage IV disease at diagnosis. Of the patients, 132 (29.3% of the cohort) underwent somatic testing; 21 of 132 (15.9%) had RAS wild-type cancers with identification of several actionable alterations, including ETV6-NTRK3, TPR-NTRK1, SCLA5-NRG1, and ATP1B1-NRG1 fusions, IDH1 R132C mutation, and mismatch repair deficiency. A total of 138 patients (30.7% of the cohort) underwent germline testing; 44 of 138 (31.9%) had a pathogenic germline variant (PGV), and 27.5% harbored alterations in cancer susceptibility genes. Of patients seen between 2015 and 2018, 30 of 193 (15.5%) had a PGV. Among 138 who underwent germline testing, those with a PGV had a reduced all-cause mortality compared with patients without a PGV controlling for stage and year of diagnosis (hazard ratio = 0.42, 95% CI = 0.26 to 0.69). PGVs are present in a substantial minority of patients with EOPC. Actionable somatic alterations were identified frequently in EOPC, enriched in the RAS wild-type subgroup. These observations underpin the recent guidelines for universal germline testing and somatic profiling in pancreatic ductal adenocarcinoma.

18 October 2021 in Leukemia
Verified
Journal Article
Closed access
PDF file
SKSiddharth Kunte
Siddharth Kunte
LRLisa Rybicki
Lisa Rybicki
AVAuro Viswabandya
Auro Viswabandya
RTRoni Tamari
Roni Tamari
ABAsad Bashey
Asad Bashey
TJTania Jain
Tania Jain